8,9) Daily or weekly administration of a GLP-1 receptor agonist
combined with basal insulin can offer a more convenient alternative to mealtime boluses of insulin.
Key clinical point: Patients with poorly controlled type 2 diabetes are more likely to hit glycemic targets if their add-on therapy is a GLP-1 receptor agonist
Researchers shed light on how GLP-1 receptor agonists
alter the brain's response to food, possibly reducing cravings and increasing satisfaction while eating.
A total of 710 cases were related to dopamine receptor agonists
, of which 48% were reported from foreign countries, said Mr.
A 26-week, multi-center, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naive subjects with T2DM inadequately controlled on a maximum tolerated dose or maximum dose according to local label of GLP-1 receptor agonist
According to Type 2 Diabetes in South Korea, market growth will be fueled by the increasing use of DPP-IV inhibitors, GLP-1 receptor agonists
and insulin analogues as well as the introduction of the novel SGLT-2 inhibitor drug class.
The company added that the 15-member panel of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) reportedly voted 12 to 2 (1 panelist did not vote) to approve the fixed-ratio combination of basal insulin glargine 100 Units/ml and GLP-1 receptor agonist
When coupled with healthy eating habits and regular physical activity, many people lose weight when taking a GLP-1 receptor agonist
Zolpidem is a nonbenzodiazepine receptor agonist
that was approved by the Food and Drug Administration in 1992 for treatment of insomnia characterized by difficulty initiating sleep.
TRK-820 is a selective kappa opioid receptor agonist
with a novel mechanism of action which differs from that for conventional drugs such as antihistamine, and it is expected that the compound will be effective for treating itching that is resistant to existing therapeutics.
Many drugs are commonly used off-label for insomnia, but the benzodiazepine receptor agonists
and the newly approved melatonin receptor agonist
ramelteon (Rozerem) are the only medications with Food and Drug Administration approval for this indication.
Buysse's first-line pharmacotherapy, used in combination with behavioral measures, is a short-acting benzodiazepine receptor agonist